Search Results

Heart Disease in Lymphoma Survivors

 

Matthew Matasar is a hematology and oncology specialist at Memorial Sloan-Kettering Cancer Center in New York City. He has a Translational Research Program grant through The Leukemia & Lymphoma Society and is investigating which Hodgkin lymphoma survivors are at greater risk for developing heart disease after receiving radiation therapy to the chest and what diagnostic tests are best.

Lymphoma diagnosis, survival rate by age, prognosis, and treatment

Table of contents:

Leukemia vs. lymphoma: What you need to know

Table of contents

Ask the Doctor Part 2: Five Questions about Lymphoma

Lymphoma survivor, Jessica Melore talks to Dr. Nichols about the Latest in Lymphoma Research and Treatment

Lymphoma

Lymphoma is the name for a group of blood cancers that develop in the lymphatic system. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL).

A New CAR-T Approval Brings Hope for Mantle Cell Lymphoma Patients

The U.S. Food and Drug Administration (FDA) today announced its approval for a breakthrough treatment that will bring the promise of immunotherapy and new hope to thousands of patients diagnosed with mantle cell lymphoma (MCL) whose previous treatments fail to bring them lasting remissions.

Every Year Counts: Celebrating My Healing from Hodgkin Lymphoma

Many blood cancer survivors remember the day they were diagnosed, and they never forget it. For Racheli Alkobey Peltier—Director of Diversity, Equity, and Inclusion at The Leukemia & Lymphoma Society (LLS)— when that date comes around, it’s a chance to mark her progress.  

Each year, Racheli marks important milestones in her experience with blood cancer—taking time to reflect, feel gratitude, and look ahead. These dates are her “cancerversaries.”  

Film Documents Actor’s Lymphoma Journey, Highlights Need for Research

 

 

Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.

My Journey Through Stage IV Non-Hodgkin Lymphoma

Brittany Daniel is an actress best known for her role in the television series “Sweet Valley High” and the film, “Joe Dirt,” and a lifestyle blogger at The Sweet Life By Brittany + Cynthia Daniel. She and her husband, Adam, will participate in The Leukemia Cup Regatta in San Francisco (www.sflcr.org) on October 22.​

Lymphoma

Please note that these resources are regularly reviewed to ensure that links still work correctly and that the resources listed continue to be helpful to our visitors. If you find that a link isn't working or information is incorrect, please email infocenter@lls.org.  If you would like for us to consider adding your organization to this resource, please complete and submit this form.

Lymphoma

Lymphoma

The Leukemia & Lymphoma Society Still Reigns “Superior” in Independent Analysis of Chronic Disease Nonprofits

CAR T-Cell Therapy Approved for Initial Treatment of Relapsed Large B-Cell Lymphoma

Hodgkin Lymphoma

Hodgkin Lymphoma (HL)

• Is a cancer that affects the lymphatic system, which is part of the body's immune system
• Is one of the most curable forms of cancer
• Is named for Dr. Thomas Hodgkin who, in 1832, described several cases of people with symptoms of a cancer involving the lymph nodes. The disease was called "Hodgkin's disease" until it was officially renamed "Hodgkin lymphoma" in the late 20th century.

Click here to access Hodgkin lymphoma statistics.

Three things you give when you give to The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society's New Chief Scientific Officer Excited about What's Next in Blood Cancer Research

Lore Gruenbaum, Ph.D., was promoted to The Leukemia & Lymphoma Society’s (LLS) Chief Scientific Officer (CSO) following the retirement of longtime CSO Lee Greenberger, Ph.D. on December 31. We talked with Dr. Gruenbaum about her new role and what’s on the horizon for blood cancer research in 2025. 

“It’s a privilege to lead a group of dedicated LLS scientists to seek out and fund innovative science for every type of blood cancer,” says Dr. Gruenbaum.  

Walgreens helps raise more than $6 million for The Leukemia & Lymphoma Society (LLS) and Susan G. Komen to Advance Cancer Research and Increase Access to Care

Join us in thanking Walgreens stores and customers across the country for raising over $6 million for LLS and Susan G. Komen during their spring campaign. Donations made at checkout at more than 9,000 U.S. Walgreens locations will be split evenly between the two organizations.

During this multi-year partnership, Walgreens has helped to donate more than $25 million by 2024 to advance research for tough-to-treat cancers and increase equitable access to care.

Hodgkin Lymphoma Subtypes

The World Health Organization (WHO) divides Hodgkin lymphoma into two main subtypes. They are:

Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma (NHL)

• Is a type of cancer that generally develops in the lymph nodes and lymphatic tissue found in organs such as the stomach, intestines or skin. In some cases, NHL involves bone marrow and blood.
• Isn't just one disease–it's actually a diverse group of blood cancers that all arise from lymphocytes (white blood cells that are part of the immune system).
• Lymphoma cells may develop in just one place or in many sites in the body.
• NHL has many different subtypes which are either indolent (slow-growing) or aggressive (fast-grow

Hodgkin Lymphoma Staging

Doctors use physical examinations, imaging tests, blood test and, sometimes, bone marrow tests to determine the extent of the disease.  This determination is called "staging."  Staging provides important information for treatment planning.

Staging for Hodgkin lymphoma is based on the Lugano classification, which is derived from the Ann Arbor staging system.

Childhood Hodgkin Lymphoma

Because of new and better therapies, cancer survival rates for children have improved dramatically during the last several decades. Scientists continue to search for the causes of childhood lymphoma so they can develop better treatments with less toxic side effects.

Next-Generation Targeted Therapy in Mantle Cell Lymphoma and Transformed Follicular Lymphoma

The field of cancer treatment has made remarkable progress with the adoption of targeted therapy; however, small molecule drugs have limitations such as drug resistance and off-target toxicities. To overcome these challenges, we have developed an innovative approach that enhances the potency and precision of small molecule drugs. Our cutting-edge high-precision pretargeted nanoparticles can deliver potent triple inhibitors that effectively combat drug-resistant mantle cell lymphoma and dual proteolysis targeting chimeras (PROTACs) for treatment of transformed follicular lymphoma.